Pancreatic Cancer Research

ResearcherChinese University of Hong KongActive in the last 2 years

Stephen Lam Chan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8998-5480; OpenAlex author ID A5046498356. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
23
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 3 papers · 2025: 1 paper · 2026: 1 paper

Papers 12

  1. RAS-targeted therapies for pancreatic cancer. Last author DOI 10.1016/j.esmogo.2026.100414↗
  2. Consensus statement on the use of systemic therapies in pancreatic ductal adenocarcinoma in Asia. Co-author DOI 10.1016/j.esmogo.2025.100158↗
  3. The molecular mechanism underlying KRAS regulation on STK31 expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/cas.16286↗
  4. PEG-BCT-100 and Canavanine Synergistically Induce Apoptosis in Arginine Biosynthetic Enzyme-Deficient Pancreatic Cancer. Last author DOI 10.1158/2767-9764.crc-24-0425↗
  5. Hong Kong consensus recommendations on the management of pancreatic ductal adenocarcinoma. Co-author DOI 10.12809/hkmj2210476↗
  6. Risks and impacts of thromboembolism in patients with pancreatic cancer. Last author DOI 10.12809/hkmj219788↗
  7. CircRTN4 promotes pancreatic cancer progression through a novel CircRNA-miRNA-lncRNA pathway and stabilizing epithelial-mesenchymal transition protein. Co-author DOI 10.1186/s12943-021-01481-w↗
  8. Ectopic HOTTIP expression induces noncanonical transactivation pathways to promote growth and invasiveness in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2020.02.038↗
  9. CircFOXK2 Promotes Growth and Metastasis of Pancreatic Ductal Adenocarcinoma by Complexing with RNA-Binding Proteins and Sponging MiR-942. Co-author DOI 10.1158/0008-5472.can-19-3268↗
  10. Impact of Weight Loss During Chemotherapy in Chinese Patients with Unresectable Pancreatic Cancer. Last author DOI 10.1080/01635581.2019.1595047↗
  11. Systemic treatment for inoperable pancreatic adenocarcinoma: review and update. Co-author DOI 10.5732/cjc.013.10134↗
  12. Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin. Co-author DOI 10.1053/j.gastro.2013.01.058↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Landon Long Chan · 3 shared papers, 2023–2026 · strength 0.85
  2. Yangchao Chen · 5 shared papers, 2013–2024 · strength 0.67
  3. Tsz Tung Kwong · 2 shared papers, 2024–2026 · strength 0.66
  4. Chi Hin Wong · 4 shared papers, 2020–2024 · strength 0.64
  5. Ksh Chok · 2 shared papers, 2024 · strength 0.42
  6. Raymond S. Y. Tang · 2 shared papers, 2023–2024 · strength 0.39
  7. Chi Han Li · 3 shared papers, 2013–2024 · strength 0.38
  8. Ut Kei Lou · 2 shared papers, 2020–2022 · strength 0.29
  9. Sohei Satoi · 1 shared paper, 2025 · strength 0.25
  10. Kyu‐pyo Kim · 1 shared paper, 2025 · strength 0.25
  11. Masafumi Ikeda · 1 shared paper, 2025 · strength 0.25
  12. Do‐Youn Oh · 1 shared paper, 2025 · strength 0.25
  13. Lin Shen · 1 shared paper, 2025 · strength 0.25
  14. Sang Myung Woo · 1 shared paper, 2025 · strength 0.25
  15. Bo Li · 1 shared paper, 2024 · strength 0.23
  16. Yuting Liu · 1 shared paper, 2024 · strength 0.23
  17. Francis P. T. Mok · 1 shared paper, 2024 · strength 0.20
  18. Chi‐Leung Chiang · 1 shared paper, 2024 · strength 0.20
  19. Charing C. N. Chong · 1 shared paper, 2019 · strength 0.12
  20. Henry C. Y. Wong · 1 shared paper, 2019 · strength 0.12
  21. Zhexi He · 1 shared paper, 2014 · strength 0.06
  22. Yinxin Zhu · 1 shared paper, 2013 · strength 0.03
  23. Zhangang Xiao · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.